Cargando…

Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis

Gliomas are the most common central nervous system malignancies and present with significant morbidity and mortality. Treatment modalities are currently limited to surgical resection, chemotherapy and radiotherapy. Increases in survival rate over the previous decades are negligible, further pinpoint...

Descripción completa

Detalles Bibliográficos
Autores principales: Kan, Liyen Katrina, Drummond, Kate, Hunn, Martin, Williams, David, O'Brien, Terence J, Monif, Mastura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871709/
https://www.ncbi.nlm.nih.gov/pubmed/33681797
http://dx.doi.org/10.1136/bmjno-2020-000069
_version_ 1783649062797443072
author Kan, Liyen Katrina
Drummond, Kate
Hunn, Martin
Williams, David
O'Brien, Terence J
Monif, Mastura
author_facet Kan, Liyen Katrina
Drummond, Kate
Hunn, Martin
Williams, David
O'Brien, Terence J
Monif, Mastura
author_sort Kan, Liyen Katrina
collection PubMed
description Gliomas are the most common central nervous system malignancies and present with significant morbidity and mortality. Treatment modalities are currently limited to surgical resection, chemotherapy and radiotherapy. Increases in survival rate over the previous decades are negligible, further pinpointing an unmet clinical need in this field. There is a continual struggle with the development of effective glioma diagnostics and therapeutics, largely due to a multitude of factors, including the presence of the blood–brain barrier and significant intertumoural and intratumoural heterogeneity. Importantly, there is a lack of reliable biomarkers for glioma, particularly in aiding tumour subtyping and measuring response to therapy. There is a need for biomarkers that would both overcome the complexity of the disease and allow for a minimally invasive means of detection and analysis. This is a comprehensive review evaluating the potential of current cellular, proteomic and molecular biomarker candidates for glioma. Significant hurdles faced in glioma diagnostics and therapy are also discussed here.
format Online
Article
Text
id pubmed-7871709
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-78717092021-03-04 Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis Kan, Liyen Katrina Drummond, Kate Hunn, Martin Williams, David O'Brien, Terence J Monif, Mastura BMJ Neurol Open Review Gliomas are the most common central nervous system malignancies and present with significant morbidity and mortality. Treatment modalities are currently limited to surgical resection, chemotherapy and radiotherapy. Increases in survival rate over the previous decades are negligible, further pinpointing an unmet clinical need in this field. There is a continual struggle with the development of effective glioma diagnostics and therapeutics, largely due to a multitude of factors, including the presence of the blood–brain barrier and significant intertumoural and intratumoural heterogeneity. Importantly, there is a lack of reliable biomarkers for glioma, particularly in aiding tumour subtyping and measuring response to therapy. There is a need for biomarkers that would both overcome the complexity of the disease and allow for a minimally invasive means of detection and analysis. This is a comprehensive review evaluating the potential of current cellular, proteomic and molecular biomarker candidates for glioma. Significant hurdles faced in glioma diagnostics and therapy are also discussed here. BMJ Publishing Group 2020-08-24 /pmc/articles/PMC7871709/ /pubmed/33681797 http://dx.doi.org/10.1136/bmjno-2020-000069 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Review
Kan, Liyen Katrina
Drummond, Kate
Hunn, Martin
Williams, David
O'Brien, Terence J
Monif, Mastura
Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis
title Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis
title_full Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis
title_fullStr Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis
title_full_unstemmed Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis
title_short Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis
title_sort potential biomarkers and challenges in glioma diagnosis, therapy and prognosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871709/
https://www.ncbi.nlm.nih.gov/pubmed/33681797
http://dx.doi.org/10.1136/bmjno-2020-000069
work_keys_str_mv AT kanliyenkatrina potentialbiomarkersandchallengesingliomadiagnosistherapyandprognosis
AT drummondkate potentialbiomarkersandchallengesingliomadiagnosistherapyandprognosis
AT hunnmartin potentialbiomarkersandchallengesingliomadiagnosistherapyandprognosis
AT williamsdavid potentialbiomarkersandchallengesingliomadiagnosistherapyandprognosis
AT obrienterencej potentialbiomarkersandchallengesingliomadiagnosistherapyandprognosis
AT monifmastura potentialbiomarkersandchallengesingliomadiagnosistherapyandprognosis